The current study characterizes the clinical, morphologic, and molecular features of multiple tumor specimens from five patients who initially had low-grade G1/G2 well-differentiated NET that underwent grade progression accompanied by the acquisition of prototypical NEC co-alteration of RB1 and TP53. This evidence concerns the gene TP53 and neuroendocrine carcinoma.